Pharmacokinetics of 10mg tablet
Pro Research Analysisby 
Searched over 200M research papers
Pharmacokinetics of 10mg Tablet: Key Parameters and Bioequivalence
Pharmacokinetics and Bioequivalence of 10mg Tablets
Multiple studies have evaluated the pharmacokinetics (PK) of 10mg tablet formulations across various drugs, focusing on parameters such as maximum plasma concentration (Cmax), area under the concentration-time curve (AUC), and bioequivalence to reference products. For example, studies on rivaroxaban 10mg tablets in healthy participants under both fasting and fed conditions found that the Cmax and AUC values for test and reference formulations were very similar, with all parameters falling within accepted bioequivalence limits. No serious adverse events were reported, confirming the safety and equivalence of the formulations 25.
Similarly, a study on ezetimibe 10mg tablets in healthy volunteers showed that both the generic and branded products had nearly identical PK profiles, with the 90% confidence intervals for Cmax and AUC within the standard bioequivalence range of 0.80 to 1.25. Both formulations were well tolerated with no adverse events .
Single vs. Multiple Dose Pharmacokinetics
For fexuprazan 10mg tablets, single and multiple dosing (twice daily) were compared. The study found that the AUC over 12 hours (AUC0–12h) after multiple doses was about double that of a single dose, as expected. Additionally, four 10mg tablets were pharmacokinetically equivalent to one 40mg tablet, meeting bioequivalence criteria for both Cmax and AUC .
Fixed-Dose Combinations and 10mg Components
Fixed-dose combination (FDC) tablets containing 10mg of active ingredients, such as dapagliflozin or rosuvastatin, have also been studied. In these studies, the PK parameters (Cmax and AUC) of the FDCs were nearly identical to those of the separate tablets, and the 90% confidence intervals for the ratios of geometric means were within the bioequivalence limits. Food had a statistically significant effect on some PK parameters, but this was not considered clinically significant 89.
Alternative Formulations: Sublingual and Intravenous
A comparison of a new 10mg sublingual temazepam tablet with a standard 10mg oral capsule found no significant differences in PK parameters, indicating similar absorption and effect profiles . For sildenafil, a 10mg intravenous bolus provided plasma concentrations similar to those achieved with a 20mg oral tablet, suggesting comparable exposure and safety .
Summary of Key Pharmacokinetic Findings
- Cmax and AUC: Across drugs and formulations, 10mg tablets consistently showed Cmax and AUC values within bioequivalence limits when compared to reference products or alternative formulations 1258+2 MORE.
- Safety: All studies reported good tolerability and no serious adverse events with 10mg tablet formulations 25910.
- Bioequivalence: Both single-ingredient and fixed-dose combination 10mg tablets were bioequivalent to their respective reference products 1258+2 MORE.
- Food Effect: While food can affect PK parameters, these changes are generally not clinically significant for 10mg tablets 258.
Conclusion
The pharmacokinetics of 10mg tablet formulations are well characterized, with studies consistently demonstrating bioequivalence, predictable absorption, and good safety profiles across a range of drugs and formulations. These findings support the use of 10mg tablets as reliable and effective options for clinical use.
Sources and full results
Most relevant research papers on this topic